WAT — Waters Corporation

Summary of Waters Corporation Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Sales: $800 million, up 8% year-over-year (YoY) and 4% quarter-over-quarter.
• Earnings: Non-GAAP EPS of $3.40, a 16% increase YoY, exceeding guidance by $0.20.
• Gross Margin: 59%, a 70 basis point increase from the previous quarter.
• Recurring Revenue: Grew 9%, with service up 7% and chemistry up 13%.
• Debt: Net debt stood at $948 million.
• Free Cash Flow: $160 million after capital expenditures and transaction-related expenses.

2. Strategic Updates and Business Highlights

• Innovation: Launched the Xevo CDMS, a breakthrough in mass spectrometry, and saw strong adoption of new products like the Alliance iS and Xevo TQ Absolute.
• Market Performance: Instrument sales grew 6%, driven by high single-digit growth in the LC-MS portfolio. Recurring revenue growth was robust, particularly in chemistry.
• Geographic Strength: Strong performance in the Americas (11% growth), Asia (13% growth), and particularly in China (20% growth).
• Pending Acquisition: Integration planning for the combination with BD's Biosciences & Diagnostic Solutions is progressing well, with expectations for synergy realization.

3. Forward Guidance and Outlook

• 2025 Guidance: Sales growth revised to a range of 6.7% to 7.3% (midpoint of 7%), and adjusted EPS guidance raised to $13.05 to $13.15, reflecting double-digit growth.
• Q4 Expectations: Anticipating constant currency sales growth of 5% to 7% and adjusted EPS of $4.45 to $4.55.
• 2026 Outlook: Positioned for continued growth driven by instrument replacement cycles, service expansion, and new product launches.

4. Bad News, Challenges, or Points of Concern

• Market Headwinds: Some segments, such as CROs and branded generics in China, are still experiencing slower growth.
• Academic & Government Segment: Growth in this area is tied to stimulus funding, which may not be sustainable long-term.
• Margin Pressure: New product launches may initially exert downward pressure on margins until they scale.
• Tax Rate Fluctuations: A projected increase in the tax rate for Q4 could impact earnings.

5. Notable Q&A Insights

• Pharma Growth: Strong performance attributed to instrument replacement cycles and new product traction, particularly in GLP-1 testing and bioanalytical characterization.
• BD Transaction: Confidence in achieving revenue synergies; integration planning is well underway, with a focus on immediate revenue opportunities.
• China's Market Dynamics: Growth driven by local CDMOs and biotech, with expectations for continued double-digit growth in the near term.
• Biosimilar Opportunity: Regulatory changes could significantly increase demand for Waters' analytical instruments, enhancing market access for biosimilars.
• Chemistry Growth: Strong performance attributed to innovation in bioseparations, with expectations for continued growth despite some pull-forward dynamics from previous quarters.

Overall, Waters Corporation reported a strong quarter with solid growth across various segments, driven by innovation and strategic execution, while also preparing for future challenges and opportunities.